ImmunityBio Inc. (IBRX)
NASDAQ: IBRXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 9.76 +0.10%
IBRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.33B
- EPS (TTM)
- -$0.97
- Dividend yield
- None
- 52-week range
- 1.95 – 12.43
- Day range
- 9.33 – 9.93
- Volume / Avg
- 11.75M / 10.26M
- Beta
- —
- Shares outstanding
- 1.06B
- Next earnings
- Nov 3, 2026
52-week range
IBRX stock today
On Oct 7, IBRX ended the session at $9.75, adding $0.06 (0.62%), versus the S&P 500's 0.22% decline. Shares are 21.6% below their 52-week high of $12.43, set on Feb 25, 2026 and 400.0% above the 52-week low of $1.95, in the middle of the past year's range. IBRX is up 392.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 290.4%.
ImmunityBio has posted a net loss over the last twelve months (EPS of -$0.97), so its P/E ratio is not meaningful. ImmunityBio's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About ImmunityBio
Company profileImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Gerald Adcock
- Headquarters
- San Diego, CA
- Employees
- 684
- IPO year
- 2015
- Website
- immunitybio.com
Financial highlights
Full financialsIn fiscal 2025, ImmunityBio generated $113.3 million in revenue, up 668.3% from fiscal 2024, its 3rd consecutive year of revenue growth. ImmunityBio reported a net loss of $351.4 million, compared with a loss of $413.6 million a year earlier. Gross margin was 99.3% (down from 100.0%) and operating margin -226.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $113.29M | $14.74M | $622.00K | $240.00K | $934.00K |
| Growth | +668.31% | +2270.58% | +159.17% | -74.30% | +54.38% |
| Net income | $-351.40M | $-413.56M | $-583.20M | $-416.57M | $-346.79M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$12.75+30.77%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.08
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.22 vs —
ImmunityBio peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs IBRX |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs IBRX |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs IBRX |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs IBRX |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs IBRX |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs IBRX |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs IBRX |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs IBRX |
Indexes, lists and sector
Appears in lists
ImmunityBio stock FAQ
What is ImmunityBio's stock price today?
IBRX last traded at $9.75 as of Oct 7, 4:00 PM EDT, up 0.62% on the day. Prices are delayed at least 15 minutes.
When is ImmunityBio's next earnings date?
ImmunityBio is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.08.
Who is ImmunityBio's CEO?
Mr. Richard Gerald Adcock is the chief executive officer of ImmunityBio Inc., which has about 684 employees.
What is the IBRX 52-week high?
The 52-week high for IBRX is $12.43 and the 52-week low is $1.95. The stock is currently 21.6% below its high.